Exercise for Disc Degeneration

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Disc Degeneration+1 MoreExercise - Other
Eligibility
21 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial is examining how well different exercises work to improve muscle function in people with chronic back pain from a herniated disc.

Eligible Conditions
  • Disc Degeneration
  • Lower Back Pain

Treatment Effectiveness

Study Objectives

1 Primary · 59 Secondary · Reporting Duration: 6 months

6 Months
Change in Oswestry Disability Index (ODI)
Hour 6
ADIPOQ Protein abundance (ug/mg)
ADIPOQ gene expression (delta CT/delta CT)
ANKRD2 gene expression (delta CT/delta CT)
ANKRD2 protein abundance (ug/mg)
CASP1 Protein abundance (ug/mg)
CASP1 gene expression (delta CT/delta CT)
CASP3 Protein abundance (ug/mg)
CASP3 gene expression (delta CT/delta CT)
CEBPA Protein abundance (ug/mg)
CEBPA gene expression (delta CT/delta CT)
COL1A1 Protein abundance (ug/mg)
COL1A1 gene expression (delta CT/delta CT)
COL3A1 Protein abundance (ug/mg)
COL3A1 gene expression (delta CT/delta CT)
COL9A1 Protein abundance (ug/mg)
COL9A1 gene expression (delta CT/delta CT)
CTGF Protein abundance (ug/mg)
CTGF gene expression (delta CT/delta CT)
FABP4 Protein abundance (ug/mg)
FABP4 gene expression (delta CT/delta CT)
IL10 Protein abundance (ug/mg)
IL10 gene expression (delta CT/delta CT)
IL1B Protein abundance (ug/mg)
IL1B gene expression (delta CT/delta CT)
IL6 Protein abundance (ug/mg)
IL6 gene expression (delta CT/delta CT)
LEP Protein abundance (ug/mg)
LEP gene expression (delta CT/delta CT)
LOX Protein abundance (ug/mg)
LOX gene expression (delta CT/delta CT)
GRB2 Adaptor Protein
MMP1 Protein abundance (ug/mg)
MMP1 gene expression (delta CT/delta CT)
MMP3 Protein abundance (ug/mg)
MMP3 gene expression (delta CT/delta CT)
MMP9 Protein abundance (ug/mg)
MMP9 gene expression (delta CT/delta CT)
MTOR gene expression (delta CT/delta CT)
MTOR protein abundance (ug/mg)
MYHC3 gene expression (delta CT/delta CT)
MYOG gene expression (delta CT/delta CT)
MYOG protein abundance (ug/mg)
PAX7 gene expression (delta CT/delta CT)
PAX7 gene expression (ug/mg)
PPARD Protein abundance (ug/mg)
PPARD gene expression (delta CT/delta CT)
PPARG Protein abundance (ug/mg)
PPARG gene expression (delta CT/delta CT)
TGFB1 Protein abundance (ug/mg)
TGFB1 gene expression (delta CT/delta CT)
TNFa Protein abundance (ug/mg)
TNFa gene expression (delta CT/delta CT)
6 months
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Change in Multifidus Muscle Fatty Infiltration
Change in Pain (VAS)
Change in Pain Catastrophizing Scale (PCS)
Change in Strength
After exercise (within 5 minutes)
Change in Activated Muscle Volume (%)
baseline
Structure of multifidus muscle

Trial Safety

Trial Design

2 Treatment Groups

Non-exercise
1 of 2
Exercise
1 of 2

Active Control

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Exercise · No Placebo Group · N/A

Exercise
Other
Experimental Group · 1 Intervention: Exercise · Intervention Types: Other
Non-exerciseNoIntervention Group · 1 Intervention: Non-exercise · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,027 Previous Clinical Trials
1,795,981 Total Patients Enrolled
Balgrist University HospitalOTHER
83 Previous Clinical Trials
511,630 Total Patients Enrolled
Spine Institute of San Diego (Spine Zone)UNKNOWN

Eligibility Criteria

Age 21 - 85 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: